New Delhi: In a major strategic expansion, Sun Pharmaceutical Industries has announced the acquisition of US-based Organon & Co. in a massive $11.8 billion (around ₹98,000 crore) all-cash deal. This marks the largest overseas acquisition in the history of the company and one of the biggest cross-border pharma deals by an Indian firm.
Under the terms of the agreement, Sun Pharma will acquire Organon at $14 per share, offering a premium of over 24% compared to its last closing price on April 24. The move is expected to significantly accelerate Sun Pharma’s global growth ambitions and diversify its revenue streams.
The acquisition gives Sun Pharma access to Organon’s strong presence in more than 140 international markets, including fast-growing regions such as China, Latin America, and Southeast Asia. It also brings a well-established portfolio spanning women’s health products, biosimilars, and a wide range of legacy pharmaceutical brands.
Industry experts believe the deal will help Sun Pharma strengthen its position in specialised and high-margin therapy areas while reducing dependence on a few key markets. The addition of Organon’s capabilities in women’s healthcare is particularly seen as a long-term growth driver.
Investors responded positively to the announcement, with Sun Pharma’s shares rising nearly 7% to close at ₹1,734 on the BSE. The deal highlights the company’s aggressive global strategy and signals growing confidence among Indian pharma firms in expanding through large-scale international acquisitions.
Ellofacts
